Discover 707 paid clinical trials in Olathe, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 707
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
for
Myelofibrosis,MF
Location: Fairway KS
Sponsor: University of Kansas Medical Center
Sex: All
Age: 18+
Code: NCT06414681
Early_phase1, Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
for
Refractory Metastatic Colorectal Cancer
Location: Fairway KS, New Orleans LA, Salt Lake City UT, Tampa FL,
Sponsor: Delcath Systems Inc.
Sex: All
Age: 18+
Code: NCT06607458
Phase2, Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
for
Gastroesophageal Adenocarcinoma
Location: Fairway KS, North Shores MI, Washington D.C. DC,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07069712
Phase2, Recruiting
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Location: Fairway KS, Chicago IL, Dallas TX, Cincinnati OH,
Sponsor: Beat AML, LLC
Sex: All
Age: 18+
Code: NCT03013998
Phase2, Phase3, Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
for
Delayed Graft Function, DGF, Kidney Transplant
Location: Fairway KS, Omaha NE, St Louis MO, Minneapolis MN,
Sponsor: Alexion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06830798
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
for
Acute Myeloid Leukemia (AML)
Location: Fairway KS, Houston TX, Augusta GA, New York NY,
Sponsor: Bio-Path Holdings, Inc.
Sex: All
Age: 18+
Code: NCT02781883
Phase2, Recruiting
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
for
cGVHD
Location: Fairway KS, Rochester MN, Maywood IL, Chicago IL,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT05919511
Recruiting
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
for
Bladder Cancer
Location: Fairway KS, Kansas City KS
Sponsor: Rahul Parikh
Sex: All
Age: 18+
Code: NCT03762161
Phase2, Recruiting
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Fairway KS, Westwood KS, Kansas City KS, Chicago IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05172245
Phase1, Recruiting
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
for
Polymyositis, Dermatomyositis
Location: Fairway KS, Allen TX, Willowbrook IL, Colleyville TX,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06455449
Phase3, Recruiting
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Location: Kansas City KS, Wichita KS, Ankeny IA, St Louis MO,
Sponsor: Valencia Technologies Corporation
Sex: All
Age: 18+
Code: NCT05685433
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML